abrdn plc Purchases 41,835 Shares of Danaher Co. (NYSE:DHR)

abrdn plc raised its stake in Danaher Co. (NYSE:DHR) by 4.0% in the 4th quarter, HoldingsChannel reports. The fund owned 1,085,291 shares of the conglomerate’s stock after buying an additional 41,835 shares during the quarter. abrdn plc’s holdings in Danaher were worth $248,684,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the stock. Heck Capital Advisors LLC acquired a new stake in shares of Danaher in the 4th quarter valued at $27,000. Decker Retirement Planning Inc. acquired a new position in shares of Danaher during the 4th quarter worth about $31,000. Teachers Insurance & Annuity Association of America acquired a new position in Danaher during the third quarter valued at approximately $39,000. MidAtlantic Capital Management Inc. bought a new stake in shares of Danaher in the 3rd quarter valued at $40,000. Finally, FSA Wealth Management LLC acquired a new stake in shares of Danaher during the third quarter worth about $50,000. Institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 10.90% of the stock is currently owned by insiders.

Danaher Stock Down 3.9 %

Shares of DHR opened at $214.09 on Tuesday. The firm has a 50 day simple moving average of $235.40 and a two-hundred day simple moving average of $253.09. The company has a market cap of $154.64 billion, a P/E ratio of 40.55, a P/E/G ratio of 2.80 and a beta of 0.83. Danaher Co. has a one year low of $214.03 and a one year high of $281.70. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, meeting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter last year, the firm posted $2.09 EPS. Research analysts forecast that Danaher Co. will post 7.77 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Friday, December 27th were given a dividend of $0.27 per share. The ex-dividend date of this dividend was Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.50%. Danaher’s dividend payout ratio is presently 20.45%.

Analysts Set New Price Targets

DHR has been the topic of a number of research analyst reports. JPMorgan Chase & Co. dropped their price objective on shares of Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a report on Tuesday, January 28th. Raymond James restated a “market perform” rating on shares of Danaher in a report on Monday. TD Cowen raised their price target on Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research note on Wednesday, October 23rd. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a report on Saturday, December 14th. Finally, Jefferies Financial Group cut their price target on Danaher from $285.00 to $260.00 and set a “buy” rating for the company in a report on Wednesday, January 29th. Seven analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $278.00.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.